HRAS and RASopathy: However consistent with previously reported mutations that contribute to Costello syndrome and other RASopathies [37], the Arg68Trp mutant activated the downstream Raf-MEK-ERK-Elk1 signaling pathway to a level intermediate between wild-type and oncogenic HRAS-Gln61Leu.